|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 完全切除的Ⅰ期,Ⅱ期和ⅢA期非小细胞肺癌术后放疗联合辅助化疗对生存率的影响:国际诺维本辅助治疗组织随机临床试验显示文摘研究背景:1998年术后放疗( post operative radiotherapy, PORT )的meta分析表明术后放疗相关死亡率风险增加21%,术后放疗的作用一直是探讨的热点。PORT对于pN0和pN1患者显示出较差的生存率,而对于Ⅲ期和pN2的患者仅轻微提高生存率。通过对术后放疗研究,辅助放疗的作用地位明显下降,随之出现的其他变化如顺铂的使用增加。 | Douillard JY Rosell R de Lena Mario 金冶宁 | 2009 | 中国癌症杂志2009，19，3： | 33 |
| 2 | 非小细胞肺癌的免疫治疗:改善患者预后的新方法显示文摘简介通常,非小细胞肺癌(non-small cell lung cancer,NSCLC)诊断已为晚期,且预后较差。目前的NSCLC标准治疗总体治愈率低,有必要开发新的治疗方法。我们在本综述中提供了最新的免疫治疗干预临床数据,该手段可能能够提高免疫系统对细胞的应答。方法我们针对临床应用免疫疗法治疗NSCLC,检索了PubMed上的文章以及最近肿瘤学术会议上的摘要。结果Ⅱ期临床研究结果表明,靶向肿瘤细胞本身或其异常表达的肿瘤标志物的疫苗治疗(mucin1,黑色素瘤相关抗原3,或表皮生长因子),有望作为NSCLC免疫疗法。非抗原免疫治疗,如抗细胞毒T淋巴细胞抗原4单克隆抗体、talactoferrin alfa和toll-样受体9拮抗剂,作用于激活的免疫系统,与肿瘤抗原无关,可用于晚期NSCLC的治疗。目前一些免疫治疗正在进行III期研究,以确定最佳治疗方案,并与NSCLC标准治疗对照,确定其临床疗效。结论越来越多的证据表明肺部肿瘤存在免疫应答。免疫治疗,包括疫苗治疗和非抗原免疫调节方法,可改善NSCLC的预后。而且,提高抗肿瘤免疫应答的治疗,与化疗有协同作用。生物标志物的明确以及免疫治疗作用机制的进一步阐明对于确定哪些患者更可能从免疫治疗中获益至关重要。 | Frances A. Shepherd Jean-Yves Douillard George R. Blumenschein 张玲 | 2013 | 中国肺癌杂志2013，16，4： | 7 |
| 3 | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial显示文摘 | JY Douillard D Cunningham AD Roth M Navarro RD James P Karasek P Jandik T Iveson J Carmichael M Alakl G Gruia L Awad P Rougier | 2000 | The Lancet2000，，9209： | 4 |
| 4 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study显示文摘 | J.A. Ajani M. Buyse M. Lichinitser V. Gorbunova G. Bodoky J.Y. Douillard S. Cascinu V. Heinemann R. Zaucha A. Carrato D. Ferry V. Moiseyenko | 2013 | European Journal of Cancer2013，，： | 3 |
| 5 | Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis显示文摘AIM To confirm previous conclusions on Saccharomyces cerevisiae(S. cerevisiae) CNCM I-3856 for irritable bowel syndrome(IBS) management.METHODS An individual patient data meta-analysis was performed on two randomized clinical trials studying the effect of S. cerevisiae CNCM I-3856 supplementation on gastrointestinal(GI) symptoms in IBS subjects. A total of 579 IBS subjects were included. Outcomes were the daily Likert scale scores of abdominal pain/discomfort and bloating [area under the curve(AUC) and weekly means], responder status, and bowel movements(stool frequency and consistency). Statistical analyses were conducted in Intent to Treat(ITT) population, IBS-C subjects and IBS-C subjects with an abdominal pain/discomfort score higher than or equal to 2 at baseline('IBS-C ≥ 2 subpopulation').RESULTS S. cerevisiae CNCM I-3856 significantly improved abdominal pain/discomfort and bloating during the second month of supplementation [AUC(W5-W8)]with improvement up to the minimal clinically relevant threshold of 10%: a 12.3% reduction of abdominal pain/discomfort in the ITT population compared to the Placebo group(P = 0.0134) has been observed. In the IBS-C ≥ 2 subpopulation, there were a 13.1% reduction of abdominal pain/discomfort and a 14.9% reduction of bloating compared to the Placebo group(P = 0.0194 and P = 0.0145, respectively). GI symptoms significantly decreased during supplementation but no statistical differences were reported between groups at the end of the supplementation period. Responder status was defined as a subject who experienced a decrease of 1 arbitrary unit(a.u.) or 50% of the abdominal discomfort score from baseline for at least 2 wk out of the last 4 wk of the study. A significant difference between groups was reported in the ITT population, when considering the first definition: subjects in the Active group had 1.510 higher odds to be a responder(reduction of 1 a.u. of abdominal pain/discomfort) compared with subjects in the Placebo group(P = 0.0240). At the end of supplementation period, stool consistency in the Active group of the ITT population was significantly improved and classified as 'normal' compared to Placebo(respectively 3.13 ± 1.197 a.u. vs 2.58 ± 1.020 a.u., P = 0.0003). Similar results were seen in the IBS-C ≥ 2 subpopulation(Active group: 3.14 ± 1.219 a.u. vs Placebo group: 2.59 ± 1.017 a.u., P = 0.0009).CONCLUSION This meta-analysis supports previous data linking S. cerevisiae I-3856 and improvement of GI symptoms, in IBS overall population and in the IBS-C and IBS-C ≥ 2 subpopulations. | Amélie Cayzeele-Decherf Fanny Pélerin Sébastien Leuillet Benoit Douillard Béatrice Housez Murielle Cazaubiel Gunnard K Jacobson Peter Jüsten Pierre Desreumaux | 2017 | World Journal of Gastroenterology2017，23，2： | 2 |
| 6 | Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action显示文摘 | V. Heinemann J.Y. Douillard M. Ducreux M. Peeters | 2013 | Cancer Treatment Reviews2013，，6： | 2 |
| 7 | Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial显示文摘 | Jean-Yves Douillard Rafael Rosell Mario De Lena Francesco Carpagnano Rodryg Ramlau Jose Luis Gonzáles-Larriba Tomasz Grodzki Jose Rodrigues Pereira Alain Le Groumellec Vito Lorusso Claude Clary Antonio J Torres Jabrail Dahabreh Pierre-Jean Souquet Julio A | 2006 | Lancet Oncology2006，，9： | 2 |
| 8 | Phase Ⅱ study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy显示文摘 | Rougier P Bugat R Douillard JY | 1997 | J Clin Oncol1997，15，1： | 1 |
| 9 | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer:a multicentre randomized trial显示文摘 | Douillard JY Cunningham D Roth AD | | 0，，： | 1 |
| 10 | Panitumumab FOL- FOX4 treatment and RAS mutations in colorectal cancer显示文摘 | Douillard JY 0liner KS Siena S | 2013 | N Engl J Med2013，369，11： | 1 |
| 11 | Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer显示文摘 | Douillard J Y Bennouna J Vavasseur F | 2000 | Cancer Inmunolother2000，49，1： | 1 |
| 12 | Adjuvant vinorel- bine plus cisplatin versus observation in patients with com- pletely resected stage Ib-IIIa non-small-cell lung cancer (adju- vant navelbine international trialist association ): a randomised controlled trial显示文摘 | Douillard JY Rosell R De Lena M | 2006 | Lancet Oncol2006，7，9： | 1 |
| 13 | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer:a multicentre randomised trial显示文摘 | Douillard JY Cunningham D Roth AD | 2000 | Lancet2000，355，9209： | 1 |
| 14 | Comparison of docetaxel and vinca alkaloid,alone or in combination with other chemotherapy agents,in the first-line treatment of advanced non-small cell lung cancer (NSCLC):a metaanalysis显示文摘 | Douillard JY Fossela F Georgoulias V | 2006 | Proc Am Soc Clin Oncol2006，24，： | 1 |
| 15 | Short range plasmon resonators probed by photoemission electron microscopy 显示文摘 | DOUILLARD L CHARRA F KORCZAK Z | 2008 | Nano Lett2008，8，3： | 1 |
| 16 | Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer:data from the randomized phase Ⅲ INTEREST trial显示文摘 | Douillard JY Shepherd FA Hirsh V | | 0，，05： | 1 |
| 17 | Molecular predic- tors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III IN- TEREST trial显示文摘 | Douillard J Y Shepherd F A Hirsh V | 2010 | J Clin Oncol2010，28，5： | 1 |
| 18 | Adjuvant vinorelbine plus cisplatin versus observation in patients with completely reseeted stage IB-IIIA non-small-cell lung cancer( Adjuvant Navelbine International Trialist Association ) : a randomised controlled trial 显示文摘 | Douillard JY Rosell R De Lena M | 2006 | Lancet Oncol2006，7，9： | 1 |
| 19 | Efficacy of 5-Fu+DDP compared to bolus 5-Fu in advanced pancreatic cacinoma:a radomized trial from the French Anticancer Centers Digestive Group (FNLCCDG) 显示文摘 | Rougier P Ducreux M Douillard JY | 1999 | Pro Am Soc Oncol1999，18，8： | 1 |
| 20 | Comparison of docetaxel and vinca alkaloid, alone or in combination with other chemotherapy agents, in the first-line treatment of advanced non-small cell lung cancer (NSCLC) : a metaanalysis 显示文摘 | Douillard J Y Fossela F Georgoulias V | 2006 | Proc Am Soc Clin Oncol2006，24，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员